PMA device
Medstone Sts Lithotripter for the Treatment of Symptomatic
Medstone Intl., Inc. · Lithotripter, Shockwave (For Treating Gallbladder Stones) (NCV, Class III) · First FDA decision Feb 5, 2001, newest Jan 28, 2003Pancreatic and bile duct disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "Medstone Sts"
MAUDE reports
7
Brand "Medstone Sts", since 2015
PubMed studies
30
Mentioning "Medstone Sts"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Medstone Sts Lithotripter for the Treatment of Symptomatic
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- MEDSTONE STS LITHOTRIPTER FOR THE TREATMENT OF SYMPTOMATIC, SOLITARY, RADIOLUCENT, NON-CALCIFIED GALLSTONESPMA supplement
P970042-S004 · Decided Jan 28, 2003 · 179 days after receipt · Normal 180 Day Track
Device type: Lithotripter, shockwave (for treating gallbladder stones) (NCV) · GI, Urology & Nephrology
- MEDSTONE STS LITHOTRIPTERPMA supplement
P970042-S002 · Decided Aug 20, 2002 · 180 days after receipt · Normal 180 Day Track
Device type: Lithotripter, shockwave (for treating gallbladder stones) (NCV) · GI, Urology & Nephrology
- MEDSTONE STS LITHOTRIPTERPMA supplement
P970042-S001 · Decided Feb 5, 2001 · 49 days after receipt · Normal 180 Day Track
Device type: Lithotripter, shockwave (for treating gallbladder stones) (NCV) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Medstone Sts", any status and sponsor, newest update first.
No registered device study names "Medstone Sts".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Medstone Sts", and for the whole product code for context.
This brand
7 reports: 7 malfunction, 0 injury, 0 death
Whole product code NCV
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
- MEDSTONE STS-TC LITHOTRIPTERMalfunction
3005655081-2020-00002 · Received Jun 13, 2020 · Event dated Jun 3, 2020
Device type: Lithotriptor, Extracorporeal Shock-Wave, Urological (LNS)
Device problem as coded: Intermittent Shock/Stimulation
Patient problem as coded: No Code Available
- MEDSTONE STS-TC LITHOTRIPTORMalfunction
3008262715-2018-00028 · Received Jul 6, 2018 · Event dated Jun 25, 2018
Device type: Lithotriptor, Extracorporeal Shock-Wave, Urological (LNS)
Device problem as coded: Disconnection
Patient problem as coded: No Known Impact Or Consequence To Patient
- MEDSTONE STS-TC LITHOTRIPTORMalfunction
3008262715-2018-00005 · Received Mar 2, 2018 · Event dated Feb 8, 2018
Device type: Lithotriptor, Extracorporeal Shock-Wave, Urological (LNS)
Device problem as coded: Device Inoperable
Patient problem as coded: No Known Impact Or Consequence To Patient
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Medstone Sts"[tiab]. The summary above synthesizes these.
- Biliary lithotripsy.
Vanderpool D, Jones RC, O'Leary JP, et al. · Am J Surg · 1989Clinical Trial, Randomized Controlled Trial
- Extracorporeal shock wave lithotripsy for ureteral calculi.
Cass AS · J Urol · 1992Review
- Comparison of first generation (Dornier HM3) and second generation (Medstone STS) lithotriptors: treatment results with 13,864 renal and ureteral calculi.
Cass AS · J Urol · 1995Clinical Trial, Comparative Study
- Comparison of first-generation (Dornier HM3) and second-generation (Medstone STS) lithotripters: treatment results with 145 renal and ureteral calculi in children.
Cass AS · J Endourol · 1996Comparative Study
- The effectiveness of shock wave lithotripters: a case matched comparison.
Alanee S, Ugarte R, Monga M · J Urol · 2010Comparative Study
- The Medstone STS: a technical review.
Hammond GW, Bass RB, Cass AS · Semin Urol · 1991
- Impact of type of anesthesia on efficacy of medstone STS lithotripter.
Lee C, Weiland D, Ryndin I, et al. · J Endourol · 2007
- Extracorporeal shock-wave lithotripsy for stones in middle third of ureter (overlying pelvic bone).
Cass AS · Urology · 1994Comparative Study
- Extracorporeal shock wave lithotripsy in morbidly obese patients.
Thomas R, Cass AS · J Urol · 1993
- Eighteen-year experience with the Medstone STS lithotripter: safety, efficacy, and evolving practice patterns.
Pedro RN, Lee C, Weiland D, et al. · J Endourol · 2008
- Postanesthesia care of the biliary lithotripsy patient.
Roberts AM · J Post Anesth Nurs · 1990
- The efficacy of gated versus nongated shockwave lithotripsy using the Medstone STS lithotriptor.
Chichakli R, Basrawala Z, Ross M, et al. · J Endourol · 2009Comparative Study
Other devices of this type
Also filed under product code NCV.
- Medstone Sts-Tc/U LithotripterMedstone Intl., Inc. · PMA 2003
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.